Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 10/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6632127 | 0.95 | ITGB3 (0.61) | ITGB3ITGA2BHRH3 | |
| SCHEMBL6144124 | 0.80 | ITGB3 (0.46) | ITGB3ITGA2BHRH3 | |
| SCHEMBL6634225 | 0.79 | ITGB3 (0.47) | ITGB3ITGA2BHRH3 | |
| SCHEMBL6071260 | 0.76 | HRH3 (0.72) | HRH3 | |
| SCHEMBL4054583 | 0.74 | HRH3 (0.63) | ITGB3ITGA2BHRH3 | |
| SCHEMBL6071362 | 0.73 | PRMT5 (0.57) | ITGB3ITGA2BHRH3PRMT5WDR77 | |
| SCHEMBL6630382 | 0.73 | DRD2 (0.47) | ITGB3ITGA2BHRH3 | |
| SCHEMBL6143807 | 0.73 | GPR119 (0.49) | ITGB3ITGA2BHRH3 | |
| Hydrochloric Acid SCHEMBL6632289 | 0.71 | HRH3 (0.55) | ITGB3ITGA2BHRH3 | |
| SCHEMBL7794705 | 0.71 | NPY1R (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539704-A1 | SUBSTITUTED AZEPINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004018432-A1 | SUBSTITUTED AZEPINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2004-03-04 | — | — | WO | disclosed |